Compare ATCH & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | BCTX |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 28.4M |
| IPO Year | 2024 | 2025 |
| Metric | ATCH | BCTX |
|---|---|---|
| Price | $0.19 | $2.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.4M | 317.7K |
| Earning Date | 05-15-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.47 | N/A |
| Revenue Next Year | $39.32 | $380.95 |
| P/E Ratio | $4.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.61 |
| 52 Week High | $1.92 | $14.68 |
| Indicator | ATCH | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 29.27 |
| Support Level | $0.18 | N/A |
| Resistance Level | $0.21 | $4.51 |
| Average True Range (ATR) | 0.02 | 0.22 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 8.50 | 9.63 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.